| Company Name: |
NCE Biomedical Co.,Ltd. |
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
- VCH-916
-
- $148.00
-
2026-07-27
- CAS:1200133-34-1
- Purity:
- Supply Ability: 10g
|
| | VCH-916 Basic information |
| Product Name: | VCH-916 | | Synonyms: | VCH-916;5-(1-Cyclohexen-1-yl)-3-[(trans-4-methoxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-2-thiophenecarboxylic acid potassium salt;VCH-916, >=98%;potassiuM 5-cyclohexenyl-3-(N-((1r,4r)-4-Methoxycyclohexyl)-4-MethylcyclohexanecarboxaMido)thiophene-2-carboxylate;VCH 916;VCH916;CS-790;VCH-916 (Free);HCV,VCH 916,VCH916,Hepatitis C virus,VCH-916,inhibit,Inhibitor | | CAS: | 1200133-34-1 | | MF: | C26H36KNO4S | | MW: | 497.73164 | | EINECS: | | | Product Categories: | | | Mol File: | 1200133-34-1.mol |  |
| | VCH-916 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder | | color | White to off-white |
| | VCH-916 Usage And Synthesis |
| Uses | VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.
IC50 Value:
Target: HCV
VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient. | | References | [1] Ludmila Gerber, Tania M. Welzel, Stefan Zeuzem. New therapeutic strategies in HCV: polymerase inhibitors. Liver International. 2013,33(s1): 85-92
[2] Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161.
[3] Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703
[4] Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164
[5] Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection |
| | VCH-916 Preparation Products And Raw materials |
|